Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha TherapiesPRNewsWire • 01/05/23
BWXT Starts Production of TRISO Fuel for First U.S. Generation IV MicroreactorBusiness Wire • 12/07/22
BWX Technologies to Announce Third Quarter 2022 Results on Monday, November 7Business Wire • 10/12/22
BWX Technologies, Inc. (BWXT) CEO Rex Geveden on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
BWX Technologies Reports Robust Second Quarter 2022 Results; Increases 2022 Revenue and Adjusted EBITDA(1) GuidanceBusiness Wire • 08/08/22
BWXT Canada Awarded CA$130 Million Component Manufacturing Contract from Bruce PowerBusiness Wire • 07/05/22
BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based ProductsBusiness Wire • 06/27/22